Sexually Transmitted Diseases (STDs) Treatment Market, by Disease Type (Gonorrhea, Syphilis, Herpes, Chlamydia, Hepatitis (HBV), Human Immunodeficiency Virus (HIV), and Others), By Therapy Type (Anti-bacterial, Anti-viral, Vaccines, and Anti-fungal), By Route of Administration (Oral, Injectable, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Geography - Size, Share, Outlook and Opportunity Analysis, 2018–2026

  • To Be Published : Oct 2018 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Sexually transmitted disease also known as venereal diseases is a clinical syndrome of infection, acquired and transmitted through sexual activity via body fluids such as semen, vaginal fluid or blood. Causative agent of STD are bacteria, parasites, yeast, and viruses. Symptoms of STDs includes skin rashes, warts, abdominal pain or genital ulcers. STDs are detected by physical examination or assays such as ELISA (Enzyme Linked Immunosorbent Assay), rapid plasma reagin blood test or antibody-absorption blood test. The sexually transmitted disease treatment market is expected to witness high growth in the forecast period (2017 – 2025), due to the factors such as increasing disease burden, governmental initiatives for increasing awareness, growing diagnosis of sexually transmitted diseases, and increasing number of pipeline products by manufacturers for treatment of these diseases.

Sexually Transmitted Diseases Treatment market – Driver

Increasing sexually transmitted disease burden is fueling growth of the STDs treatment market. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to Centers for Disease Control and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015. Furthermore, 468,514 gonorrhea cases were reported for a rate of 145.8 cases per 100,000 population, an increase of 18.5% from 2015. This increasing incidence of STDs is also due to the unprotected sexual practice, which in turn fueling demand for STDs treatment. For instance, according to World Health Organization (WHO), unsafe sex is second most common risk factor for increasing disease burden.

The number of products in pipeline for HIV treatment are high, which is expected to propel growth of the sexually transmitted disease treatment market. For instance, in 2017, GSK and ViiV Healthcare applied in European Medicines Agency (EMA) and US Food and Drug Administration (FDA), for regulatory affiliation for a single-tablet, two-drug regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used for treatment of HIV-1 infection. Moreover, other drug candidates in pipeline includes – PrEP, PRO140 with ibalizumab, BMS- 955176, which are expected to be launched in the forecast period. Moreover, governments are focusing on funding research and development programs, which is expected to aid in growth of the market. For instance, British Columbia Center for Disease Control sponsored doxycycline (drug) studies for indication of syphilis and other sexually transmitted infection, which is in early phase I clinical trial as of 2016.

Moreover, increasing governmental initiatives to spread awareness through organization of campaigns and free diagnostic camps is also expected to augment growth of the STDs treatment market. For instance, Centers for Disease Control and Prevention (CDC) launched Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies, or STD-AAPPS, in 2014. Moreover, in 2018, Thunder Bay Group—HIV / AIDS / hepatitis C education and support services provider— expanded the access of hepatitis C medicine for individuals with level 2 hepatitis C, after  negotiating with the provinces and drug manufacturers.

However, growth of the sexually transmitted disease treatment market is expected to be restrained by low rate of screening for diseases and late diagnosis of the disease such as HIV.  

Sexually Transmitted Diseases Treatment market - Regional Analysis

Geographically, the sexually transmitted diseases treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant market, owing to rising government initiative for disease awareness and implementation of prenatal screening programs. However, Asia Pacific is expected to be fastest growing market for sexually transmitted diseases treatment, due to high incidence of sexually transmitted infections, owing to unprotected sexual practices in the region. For instance, according to Joint United Nations Programme on HIV and AIDS (UNAIDS), Asia Pacific had the second-highest number of people living with HIV in the world i.e. 5.1 million as of 2016, Moreover, China, India, and Indonesia accounts for three quarters of the total people living with HIV in Asia Pacific.

Sexually Transmitted Diseases Treatment market – Competitor

Major players in highly fragmented sexually transmitted diseases treatment market are Merck & Co. Inc., Pfizer INC, GlaxoSmithKline Plc, Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson and Bristol-Myers Squibb. Key players in sexually transmitted disease treatment market are focusing on adopting strategies such as mergers and collaborations for expanding their research for candidate drugs. For instance, in 2017, the drug Zoloflodacin entered into clinical trials, as a result of partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Moreover, in March 2018, Inovio Pharmaceuticals, Inc. entered into a deal with ApolloBio Corp., which have the exclusive rights for development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA immunotherapy product for pre-cancer indication.

Sexually Transmitted Diseases Treatment market - Taxonomy

By Disease Type

  • Gonorrhea
  • Chlamydia
  • Syphilis
  • Herpes
  • Hepatitis (HBV)
  • Human Immunodeficiency Virus (HIV)
  • Other Indications

 By Therapy Type

  • Anti-bacterial drugs
  • Anti-viral drugs
  • Anti-fungal drugs

By Route of Administration

  • Oral
  • Injectable
  • Topical

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.